Abstract Details

Utilizing a Wearable Smartphone-based EEG for Pediatric Epilepsy Patients in the Resource Poor Environment of Guinea: A Prospective Study
Epilepsy/Clinical Neurophysiology (EEG)
N5 - Neuroscience in the Clinic: Wearable Technology (4:30 PM-4:45 PM)
001

There is a need for reliable, accessible and cost efficient EEG technologies in resource-limited settings. The SBS-2 is a portable, wearable device utilizing a 14 channel EasyCap administered by personnel easily after a few hours training. Data are transmitted via a wireless android tablet and read remotely by specialist neurophysiologists.

 

To compare the ability of a smartphone-based app, the Smartphone Brain Scanner-2(SBS2), and pre-placed  EEG cap (Easycap), costing ~300USD, to detect abnormalities with that of standard EEG.

 

Children were enrolled at Ignace Deen Hospital, Conakry, in November 2017. Participants met the ILAE definition of epilepsy and sequentially had a standard 21 lead Xltek EEG and a 14 lead EasyCap EEG utilizing SBS-2 technology. EEGs were read remotely by specialist clinical neurophysiologists in the USA and Canada. Quality scores (0-10, 0 being totally uninterpretable, 10 perfect ) were also provided.

 

97 patients (49 male, mean age 10 years) were enrolled.  One standard (1.0%) and 11(11.3%) of SBS-2 EEGs were uninterpretable due to artefact. Mean quality scores were 7.37 and 6.76 for standard and SBS-2 EEG. Two patients had a standard EEG but not an SBS-2 EEG, yielding 83 pairs of studies for analysis. Mean recording time for standard and SBS-2 EEGs was 22.9 and 27.9 minutes respectively.  Fifty-six(67.4%) standard EEGs and 31(37.3%) SBS-2 EEGs were abnormal. The sensitivity and specificity for any abnormality was 0.52 (CI 0.378,0.658) and 0.93 (CI 0.801,1.00). Epileptiform discharges were detected on 21 (25.3%) SBS-2 and 30 (36.1%) of standard EEGs. The SBS-2 had a sensitivity of 0.52 (CI 95% 0.324,0.708) and a specificity of 0.90(CI 95% 0.814,.944) for epileptiform discharges with positive and negative predictive values of 0.762 and 0.758.

 

The SBS-2 application and EasyCap wearable device is easy to administer, moderately sensitive but highly specific for detection of EEG and epileptiform abnormalities in pediatric epilepsies.

 
Authors/Disclosures
Jennifer Williams, MD (Massachusetts General Hospital, Brigham, Harvard)
PRESENTER 		No disclosure on file
No disclosure on file
No disclosure on file
No disclosure on file
No disclosure on file
No disclosure on file
No disclosure on file
Andrew Lim, MD (Univ Toronto / Lim and Hew Med Prof Corp) Dr. Lim has received personal compensation in the range of $500-$4,999 for serving on a Scientific Advisory or Data Safety Monitoring board for Eisai Canada.
Edward C. Leung, MD (Health Sciences Centre) No disclosure on file
No disclosure on file
Tracey A. Milligan, MD, FAAN Dr. Milligan has nothing to disclose.
Vidita Khatri, MD No disclosure on file
Daniel Hoch, MD, PhD, FAAN (Massachusetts General Hospital) No disclosure on file
Manav Vyas, MD (MV VYAS MEDICINE PROFESSIONAL CORPORATION) The institution of Dr. Vyas has received research support from Heart and Stroke Foundation of Canada . The institution of Dr. Vyas has received research support from Canadian Institutes of Health Research . Dr. Vyas has received research support from Heart and Stroke Foundation of Canada .
Alice D. Lam, MD, PhD Dr. Lam has received personal compensation in the range of $5,000-$9,999 for serving as a Consultant for Neurona Therapeutics. Dr. Lam has received personal compensation in the range of $500-$4,999 for serving as a Consultant for Acadia Pharmaceuticals. The institution of Dr. Lam has received research support from Neurona Therapeutics.
Gladia C. Hotan (Department of Brain and Cognitive Sciences, MIT) Ms. Hotan has received research support from Institute of High Performance Computing.
No disclosure on file
No disclosure on file
Farrah J. Mateen, MD, PhD, FAAN (Massachusetts General Hospital) Dr. Mateen has received personal compensation in the range of $5,000-$9,999 for serving on a Scientific Advisory or Data Safety Monitoring board for Horizon Therapeutics (Amgen). Dr. Mateen has received personal compensation in the range of $500-$4,999 for serving on a Scientific Advisory or Data Safety Monitoring board for Genentech. Dr. Mateen has received personal compensation in the range of $500-$4,999 for serving on a Scientific Advisory or Data Safety Monitoring board for EMD Serono. Dr. Mateen has received personal compensation in the range of $500-$4,999 for serving as an Editor, Associate Editor, or Editorial Advisory Board Member for Neurology. The institution of Dr. Mateen has received research support from Genentech. The institution of Dr. Mateen has received research support from EMD Serono. The institution of Dr. Mateen has received research support from Novartis. The institution of Dr. Mateen has received research support from Horizon Therapeutics (Amgen). The institution of Dr. Mateen has received research support from TG Therapeutics. Dr. Mateen has received intellectual property interests from a discovery or technology relating to health care.